Connexios Life Sciences, a Bangalore-based biotechnology company, and Boehringer Ingelheim, one of the world’s leading pharmaceutical companies, announced an exclusive global research collaboration agreement for AMPK agonists for the treatment of patients with Type II Diabetes.
As part of the agreement, Boehringer Ingelheim obtains global rights to CNX-012, Connexios Life Sciences’ programme on AMPK activators. The programme includes CNX-570 and other compounds in early pre-clinical development. Boehringer Ingelheim will be responsible for all further development and commercialisation of the candidates from the AMPK programme. Further terms and financial details were not disclosed.
“As a pure research-driven organisation from India, we believe that the agreement with Boehringer Ingelheim is a big validation of both our scientific approach and capabilities as well as of our business model,” commented Suri Venkatachalam, Chief Executive Officer and Founder of Connexios. “CNX-012 is one of our flagship programmes which leverages our Network Biology approach and platform and we are pleased to be working with Boehringer Ingelheim to advance candidates from this programme. We strongly believe that the collaboration will yield best-in-class activators of this exciting but challenging target and ultimately result in better therapies for patients of Type II diabetes who also suffer from the burden of several other cardiometabolic co-morbidities.”
“Partnering is key to our business strategy and the partnership with Boehringer Ingelheim who have shown a strong commitment to the therapeutic area of metabolic diseases is an important milestone for Connexios. With our strengths in disease biology and drug discovery, we see great complementarity between the organisations and look forward to building on this relationship in future,” added Shobha Vijayaraghavan, Vice President, Business Development, Connexios Life Sciences.
Commenting on the agreement, Michel Pairet, Senior Vice President and Global Head of Research and Development, Boehringer Ingelheim said: “We are pleased to enter into this agreement with Connexios, a company recognised as experts in their field, which will further strengthen our discovery and development efforts in the area of cardiometabolic diseases.”
EP News Bureau– Mumbai
- Advertisement -
